Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN1908-1909 in cat-allergic asthma
NCT03838731Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2019
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cat allergy and asthma comparing REGN1908-1909 with Placebo (2 arms). Primary endpoint: Time to Early Asthmatic Response Upon Controlled Cat Allergen Challenge at Day 8. Started Feb 2019; status: completed.
02
Drugs
freneslerbartmevonlerbart
03
Conditions
cat allergyasthma
Beyond the preview
Go deeper on NCT03838731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03838731.